Valby, Denmark – October 18, 2026 -- H. Lundbeck A/S plans to install former Novo Nordisk CEO Lars Fruergaard Jørgensen as Chair of its Board after the 2027 Annual General Meeting (AGM), succeeding Dorothea Wenzel, who will step down at that meeting.

Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.

Copenhagen – September 25, 2026 -- H. Lundbeck A/S will relocate its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts, establishing a global innovation hub in the region over the next year.

Valby, Denmark – – September 18, 2026 -- H. Lundbeck A/S has secured marketing authorization from Japan's Ministry of Health, Labour and Welfare for eptinezumab, branded Vyepti, as a preventive treatment for migraine attacks in adults, opening the company's first independent product launch in the country.